INTRODUCTION
============

Liver cirrhosis is an irreversible result of advanced liver disease and treatment usually focuses on preventing progression and complications. Although liver transplantation (LT) provides the only curative treatment \[[@b1-kjim-2015-267]\], LT is restricted by lack of donor organs, operative damage, and risk of rejection and high cost of the procedure \[[@b2-kjim-2015-267]\]. Therefore, an alternative therapy to improve the liver function of cirrhotic patients with minimally invasive procedures is urgently needed.

Adult stem cell-based regenerative therapies are evolving as viable clinical alternatives. There have been several reports that bone marrow stem cells (BMSCs) could accelerate the recovery and improvement of liver function in animal models of liver injury \[[@b3-kjim-2015-267]-[@b5-kjim-2015-267]\]. The potential of BMSCs to differentiate into human hepatocytes had been identified in liver biopsies after sex-mismatched orthotopic LT \[[@b6-kjim-2015-267],[@b7-kjim-2015-267]\]. The intriguing capability of blood-derived stem cells that differentiate into multiple cell lineages raises the exciting opportunity of using these cells for tissue repair \[[@b8-kjim-2015-267]\]. In humans, Alison et al. \[[@b7-kjim-2015-267]\] and Theise et al. \[[@b6-kjim-2015-267]\] demonstrated that hepatocytes could also be derived from bone marrow cell populations, although the degree of hepatic engraftment of stem cells into the human liver appeared to be highly variable.

The clinical experience in using adult stem cells for the treatment of liver damage is limited. Only a few clinical studies have been reported in which BMSCs or granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood hematopoietic stem cells could contribute to the liver function \[[@b9-kjim-2015-267]-[@b12-kjim-2015-267]\]. A previous study showed that peripheral blood monocyte cells (PBMCs) from patients with hepatitis B virus-related decompensated liver cirrhosis could differentiate into functional hepatocytes and contribute to liver function \[[@b13-kjim-2015-267]\]. Although the preliminary results seemed attractive, there has been no consensus in the source of adult stem cells and the route of cells transfer to evaluate the safety and efficacy of stem cell therapy in cirrhotic patients. In the light of these findings, we conducted a prospective clinical study of G-CSF-mobilized PBMC transplantation through ultrasound-guided percutaneous portal vein puncture in cirrhotic patients to determine whether clinical safety and benefit was conferred.

METHODS
=======

Patients
--------

From July 2012 to January 2013, 14 cirrhotic patients were screened from affiliated hospitals of Seoul National University Hospital. Inclusion criteria were as follows: age 20 to 79 years, decompensated liver cirrhosis with Child-Turcotte-Pugh (CTP) score 8 or 9 (including patients who have no radiologic evidence of remnant hepatocellular carcinoma \[HCC\] for more than 2 years after treatment). Exclusion criteria were as follows: age less than 20 or more than 80 years; serum hepatitis B surface antigen positive; who had not abstained from alcohol for at least 6 months; active status of HCC (except patients who have no radiologic evidence of remnant HCC for more than 2 years after treatment); history of hemochromatosis and/or autoimmune hepatitis; pregnant women or lactating women; hemoglobin \< 8 g/dL (male)/7.5 g/dL (female) or white blood cell \< 1,500 mm^3^ or neutrophils \< 500/mm^3^ or platelet count \< 50,000/mm^3^ ; serum creatinine \> 1.5 × normal upper limit or creatinine clearance \< 60 mL/min; presence of signs of malignant tumors or tumor suspected symptoms or history of malignant tumors with recurrence rate greater than 20% within 2 years; gastrointestinal bleeding within the last 3 months or if there is a history of spontaneous bacterial peritonitis; presence of portal vein thrombosis; presence of acute infections. The total number of enrolled subjects consisted of nine patients. This study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1110-126-383) and a written informed consent was obtained from each patient (NCT01503749).

G-CSF mobilization and PBMC transplantation therapy
---------------------------------------------------

The patients were randomized into three groups: (1) group 1 (control) did not receive any intervention regarding to PBMCs; (2) group 2 received G-CSF mobilization at a dose of 5 µg/kg/day subcutaneously for 3 days; and (3) group 3 received PBMCs transplant therapy. A random number table was used for simple randomization of subjects \[[@b14-kjim-2015-267]\]. PBMCs were mobilized with G-CSF at a dose of 5 µg/kg/day, administered subcutaneously daily for 3 days to induce the bone marrow derived PBMCs stem cells into the peripheral blood. On the day 4th, PBMCs were collected by means of apheresis using COBE SPECTRA Apheresis System (Terumo BCT Ltd., Hong Kong). The duration of the procedure up to 3 hours until the number of PBMC reached to 1.67 × 10^9^ -- 2 × 10^10^/50 mL. Then 1.67 × 10^9^ -- 2 × 10^10^/50 mL PBMC were administered centrally to the patient at an infusion rate of 10 mL/min through the ultrasound-guided percutaneous right portal branch puncture using 21 gauge TSK SONORI ject access needle (TSK Laboratory, Tochigi, Japan). Patients were discharged after 24 hours of bed rest.

Follow-up
---------

Recruitment started in July 2012. The first patient in group 1 was recruited in August 2012, the first patient in group 2 in August 2012, and the first patient in group 3 in July 2012. The CTP score and model for end-stage liver disease (MELD) score were calculated to assess the overall condition of the patients with decompensated liver cirrhosis at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24. After treatment, all patients were followed-up for 6 months. Patients abstained from alcohol and did not receive antiviral therapies, such as pegylated interferon and ribavirin during follow-up period. Albumin was replaced only when paracentesis was performed. At baseline and after 6 months follow-up, abdominal imaging (ultrasonography or computed tomography) was performed for evaluation of patency of portal vein, ascites or surveillance of HCC.

Statistical analysis
--------------------

Changes in laboratory data from baseline to 6 months after treatment among study groups were analyzed. All data are expressed as median and range, unless otherwise indicated. The comparative liver functions of the three groups were investigated by analysis of the Wilcoxon's signed ranks test (group 1 vs. 2 and group 1 vs. 3). Statistical analysis was done using SPSS version 19.0 (IBM Co., Armonk, NY, USA) and *p* values \< 0.05 were considered statistically significant.

RESULTS
=======

Demographic and clinical characteristics of the patients
--------------------------------------------------------

Nine patients who fulfilled the inclusion and exclusion criteria were included in the study. The clinical profile was similar across the study groups ([Table 1](#t1-kjim-2015-267){ref-type="table"}). There were two male patients in group 1 (male/female, 2:1), one male patients in group 2 (male/female, 1:2), and two male patients in group 3 (male/female, 2:1; *p* = 1.000). The median age (61 years \[range, 45 to 65\] in group 1, 59 years \[range, 59 to 68\] in group 2, and 65 years \[range, 54 to 71\] in group 3; *p* = 0.646) was comparable in three groups. Five patients (55.6%) had hepatitis C virus-related liver cirrhosis and alcoholic liver cirrhosis was seen in four patients (44.4%). Puncture site of portal vein and injected cell number in each patient were summarized in [Table 2](#t2-kjim-2015-267){ref-type="table"}.

Changes in laboratory data after treatment
------------------------------------------

At baseline, biochemical markers including total bilirubin, albumin, prothrombin time, creatinine, aspartate aminotransferase, alanine aminotransferase, the CTP scores, and the MELD scores were comparable in study groups. PBMC transplantation therapy showed a tendency to improve in median CTP scores at weeks 24 compared to baseline ([Fig. 1](#f1-kjim-2015-267){ref-type="fig"}). However, there were no significant reductions in the median CTP and MELD scores among study groups probably due to small sample size ([Fig. 2](#f2-kjim-2015-267){ref-type="fig"}). In addition, there were no statistical differences in the median CTP and MELD scores among different etiologies of chronic liver diseases.

Clinical outcome of the participants
------------------------------------

During the 6 months of follow-up, there was no mortality in study groups. None of patients in the study groups experienced variceal bleeding, hepatorenal syndrome, or spontaneous bacterial peritonitis. In group 1, one patient had a hepatic encephalopathy 2 months after enrollment (treated with lactulose enema). None of patients in group 2 and group 3 experienced hepatic encephalopathy. Three patients underwent paracentesis with albumin replacement (dosage of 20 g/each session): one patient at week 16 and 24 in group 1, one patient at week 20 in group 2, and one patient at week 12 (with thoracentesis) in group 3. HCC was not developed in all study patients during the follow-up period.

Adverse events
--------------

G-CSF therapy was very well tolerated in our patient group. None of the patients received G-CSF mobilization had splenic rupture during the study period. In addition, there was no bleeding or infection after portal administration of PBMCs. All of patients in group 3, imaging studies showed patent portal veins at the end of 6 months follow-up period. There were no significant adverse events related with G-CSF mobilization or PBMC transplantation during follow-up. Complications of the patients in group 1 were as follows: one patient had gingival bleeding, abdominal pain, and diarrhea. Complications of the patients in group 2 were as follows: one patient had abdominal pain, nausea, diarrhea, and hyperkalemia (treated with kalimate). There was no complication in group 3.

DISCUSSION
==========

This is the first study to present detailed transplantation procedures of autologous PBMCs to cirrhotic patients through the direct percutaneous needle puncture of portal vein under guidance of ultrasound. In this prospective controlled study, we have demonstrated the safety and potential of PBMC transplantation therapy for cirrhotic patients.

Intraportal administration of stem cells has been tried in four previous studies. In the first study, the portal catheter was introduced by minilaparotomy under general anesthesia and CD133^+^ bone marrow cells were administered through the portal catheter to three cirrhotic patients \[[@b11-kjim-2015-267]\]. In the second study, autologous CD34^+^ cells were injected into the portal vein under computer tomography (CT) scan \[[@b12-kjim-2015-267]\]. In the third study, a portal venogram was performed by percutaneous liver puncture under ultrasound guidance but infusion of CD34+ cells was performed via angiographic catheter under C-arm CT monitoring \[[@b15-kjim-2015-267]\]. In the fourth study, the authors just stated that they delivered stem cells via one of the main branches of the portal vein under ultrasound guidance but they did not provide a well-described protocol of portal application \[[@b16-kjim-2015-267]\]. Therefore, this study had several superiorities over previous studies, including transient minimal invasiveness from percutaneous portal vein needle puncture, avoidance of radiation hazards from CT scan by using ultrasound-guidance, and providing a detailed protocol of portal application. In addition, it is important to note that direct portal application may have eased to some extent the homing mechanisms, physiologically required to attract circulating extrahepatic stem cells to the regenerating liver. Moreover, after the PBMCs were re-infused into the portal vein through the ultrasound-guided direct percutaneous needle puncture in this study, no bleeding or thrombotic episode was observed. Therefore, ultrasound-guided percutaneous portal transplantation of autologous PBMCs is assumed to be a well-tolerated therapy for cirrhotic patients.

Different types of stem cells are theoretically eligible for liver regeneration. These include fetal annex (placenta and cord blood) and embryonic stem cells \[[@b17-kjim-2015-267],[@b18-kjim-2015-267]\], induced pluripotent stem cells \[[@b19-kjim-2015-267]\], hepatoblasts, and adult stem cells including hepatic progenitor cells, unsorted mononuclear stem cells, hematopoietic stem cells, and mesenchymal stem cells \[[@b20-kjim-2015-267]-[@b22-kjim-2015-267]\]. However, there have been no large randomized, controlled clinical trials comparing the efficacy of different types of stem cells. Currently, the most promising source for stem cell-based therapies is represented by the infusion of hematopoietic stem cells \[[@b23-kjim-2015-267]\]. In this regard, we adopted PBMCs (traceable using CD34 and CD133 markers) as source of stem cells obtained from peripheral collection through leukapheresis after G-CSF administration which requires no additional invasive bone marrow aspiration and/or *ex vivo* manipulation \[[@b20-kjim-2015-267],[@b24-kjim-2015-267]\]. G-CSF alone has been also tried in liver regeneration because of its ability to increase the number of circulating BMSCs, to enhance mononuclear stem cells homing to the liver, and to promote healing in the cirrhotic liver \[[@b25-kjim-2015-267],[@b26-kjim-2015-267]\]. Although G-CSF administration can be also associated with the risk of spleen enlargement or even rupture in a healthy donor \[[@b27-kjim-2015-267],[@b28-kjim-2015-267]\], Lorenzini et al. \[[@b29-kjim-2015-267]\] demonstrated the safety of BMSC mobilization and collection through leukapheresis in cirrhotic patients. G-CSF administration was also safe and induced no serious adverse events in this study, but there was no significant clinical improvement over control group. The result of this study was consistent with previous studies evaluating G-CSF treatment, which demonstrated no clinical benefit \[[@b21-kjim-2015-267],[@b30-kjim-2015-267]-[@b32-kjim-2015-267]\].

Although the mechanisms involved in stem cell therapy are not yet fully understood, some theories have been proposed \[[@b33-kjim-2015-267],[@b34-kjim-2015-267]\]. One is that genomic plasticity evokes the trans-differentiation of stem cells into functioning hepatocytes in response to the microenvironment \[[@b35-kjim-2015-267]\]. Another mechanism is presumably related to the cell fusion of BMSCs and hepatocytes \[[@b36-kjim-2015-267]\]. It is crucial to understand the homing processes of stem cells to the liver and to elucidate the relationships that exist not only between stem cells and hepatocytes (regeneration) but also between mesenchymal stem cells, myofibroblasts and stellate cells (fibrogenesis). In addition, it has been suggested that stem cells may act through the delivery of specific substances (cytokines and growth factors), rather than through trans-differentiation or cell fusion, suggests that improvements in liver function might be temporary \[[@b37-kjim-2015-267],[@b38-kjim-2015-267]\]. This hypothesis is supported by the results of the majority of the clinical trials: the improvement in laboratory data and CTP and MELD scores did not persist longer than 3 to 6 months regardless of the type of BMSCs infused, the route of delivery or the etiology of the disease. In addition, the histological evaluations support this hypothesis, as an increase in liver progenitor cells count was documented, peaking 3 months after stem cells infusion. According to the meta-analyses, stem cell therapy could improve the liver function without any severe procedure-related complications, but this improvement was insignificant compared with conventional treatment and not sustained at the 12th postoperative months \[[@b39-kjim-2015-267]\]. Although this study was a pilot study and too small to make any comment regarding efficacy, autologous PBMCs administration showed only minimal significant clinical improvement over control group in our study. These results suggest that repeated cycles of stem cell therapy could be useful to obtain a sustained significant clinical benefit.

Ultrasound-guided percutaneous portal transplantation of autologous PBMCs to cirrhotic patients, although promising, needs to be further evaluated in large randomized, controlled clinical trials with repeated cycles of therapy. A better understanding of the action of stem cells in the context of a fibrotic liver might allow more rational use of autologous PBMC therapy in liver cirrhosis.

KEY MESSAGE
===========

1\. This is the first study to present detailed transplantation procedures of autologous peripheral blood monocyte cells (PBMCs) to cirrhotics through the direct percutaneous needle puncture of portal vein under guidance of ultrasound.

2\. Direct portal transplantation of PBMCs for cirrhotic patients is a safe therapeutic modality.
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![The procedure of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cells (PBMCs). (A) Right portal vein (yellow arrows) was visualized by ultrasound. (B) After subcutaneous and subcapsular anesthesia by lidocaine, puncture needle (white arrows) was introduced into the portal vein through liver parenchyma while patient held breath for 10 seconds. Hyperechoic flow was observed in the portal vein during infusion of PBMCs through the puncture needle.](kjim-2015-267f1){#f1-kjim-2015-267}

![Post-transplantation follow-up of patients. (A) Changes in Child-Turcotte-Pugh score. (B) Changes in model for end-stage liver disease (MELD) score. G-CSF, granulocyte-colony stimulating factor; PBMC, peripheral blood monocyte cell.](kjim-2015-267f2){#f2-kjim-2015-267}

###### 

Demographic and clinical characteristics of patients

  Characteristic           Group 1 (n = 3)   Group 2 (n = 3)   Group 3 (n = 3)                                                    
  ------------------------ ----------------- ----------------- ----------------- -------- --------- --------- --------- --------- ---------
  Age (yr)/sex             65/M              61/M              45/F              59/F     68/F      59/M      65/M      54/M      71/F
  BMI, kg/m^2^             28.64             28.76             15.35             18.78    25.81     20.52     19.97     26.54     24.43
  Etiologies               HCV               Alcohol           Alcohol           HCV      HCV       Alcohol   HCV       Alcohol   HCV
  HCV titer, IU/mL         474,169           NA                NA                48,771   291,691   NA        236,758   NA        841,060
  Ascites                  Yes               No                Yes               Yes      No        Yes       Yes       Yes       Yes
  Encephalopathy           No                No                No                No       No        No        No        No        No
  Total bilirubin, mg/dL   2.2               4.5               5.4               6.3      3.4       7.2       3.9       3.5       2.9
  Albumin, g/dL            3.2               2.9               3.4               2.8      2.4       2.8       3.3       3.2       3.4
  Prothrombin time, INR    1.14              1.91              1.26              1.66     1.62      1.68      1.12      1.67      1.3
  Creatinine, mg/dL        1.26              0.59              0.85              0.86     0.66      0.7       0.9       0.73      0.6
  MELD score               13.1              19.4              15.4              19.1     16.5      19.7      12.8      16.9      13
  CTP score                8                 9                 9                 9        9         9         9         9         8
  Diabetes                 Yes               None              None              None     None      Yes       Yes       None      None

BMI, body mass index; HCV, hepatitis C virus; NA, not available; INR, international normalized ratio; MELD, model for endstage liver disease; CTP, Child-Turcotte-Pugh.

###### 

PBMC cell numbers and injection routes

                                  Patient 7           Patient 8           Patient 9
  ------------------------------- ------------------- ------------------- -------------------
  Injected cell number of PBMCs   1.67 × 10^9^        1.18 × 10^10^       2.0 × 10^10^
  Route of infusion               Right portal vein   Right portal vein   Right portal vein

PBMCs, peripheral blood monocyte cell.
